肿瘤细胞治疗研究
英文原题：Current Treatments in Mantle Cell Lymphoma.
套细胞淋巴瘤（MCL）以生物学异质性和临床表现多样为特征。
套细胞淋巴瘤（MCL）以生物学异质性和临床表现多样为特征。历史上，与其他非霍奇金淋巴瘤相比，它一直与不良预后相关。随着对该疾病生物学、分子发病机制和新疗法的更好理解，其结局已逐渐改善。高风险突变的识别带来了更好的预后判断，并为风险适应治疗策略铺平了道路。尽管化学免疫治疗仍是前线治疗的主要支柱，但纳入新型药物的联合治疗，如Bruton酪氨酸激酶抑制剂、B细胞淋巴瘤抑制剂和免疫调节剂，正在研究中，并显示出有希望的结果。CAR-T 细胞疗法和双特异性T细胞衔接器为治疗开辟了新途径。同样有前景的是抗体-药物偶联物，如ROR1抑制剂和PI3K抑制剂，这些正在临床研究中。我们概述了在MCL中发现的分子突变以及该疾病不断演变的治疗策略。
Mantle cell lymphoma (MCL) is characterized by heterogeneous biology and varied clinical presentations. Historically, it has been associated with a poor prognosis when compared with other non-Hodgkin lymphomas. With a better understanding of the disease biology, molecular pathogenesis, and new treatments, the outcomes have been gradually improving. Identification of high-risk mutations has resulted in better prognostication and paved the way for risk-adapted treatment approaches. Although chemoimmunotherapy remains the mainstay frontline treatment, combination therapies incorporating novel agents such as Bruton tyrosine kinase inhibitors, B-cell lymphoma inhibitors, and immunomodulatory agents are being studied, with promising results. Chimeric antigen receptor T-cell therapy and bispecific T-cell engagers have opened a new avenue for treatment. Also promising are antibody-drug conjugates such as ROR1 inhibitors and PI3K inhibitors, which are under clinical investigation. We provide an overview of the molecular mutations identified in MCL and the evolving treatment strategies for this disease.
MEMBER ACCOUNT
登录成功会直接打开下一页。
